化疗的心脏毒性:一个多OMIC视角
Yan Ma1, Mandy O J Grootaert2,3, Raj N Sewduth1
1VIB-KU Leuven Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
Journal of xenobiotics
|January 23, 2025
概括
化疗在癌症患者中引起严重的心脏问题,导致心律失常和心力衰竭等并发症. 新的多学科研究寻求新的生物标志物和疗法,以预防化疗诱导的心脏毒性并改善癌症幸存者的结果.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 心血管方面的并发症.
- 癌症治疗副作用 癌症治疗副作用
背景情况:
- 化疗引起的心脏毒性是癌症治疗中的一个主要问题,在10%的患者中引起显著的心血管并发症.
- 由于癌症治疗,肺癌患者特别容易发生心律失常,心力衰竭和其他心脏问题.
- 心脏毒性影响会损害心肌细胞,导致收缩能力受损和纤维化,随着重复治疗,风险会升级.
研究的目的:
- 探索化疗剂的异生物性质及其对心血管健康的有害影响.
- 确定用于早期检测心脏毒性的新生物标志物.
- 在癌症幸存者中发现新的治疗点,以减轻化疗引起的心脏毒性.
主要方法:
- 关于化疗引起的心脏毒性的现有文献的综述.
- 分析多omics数据,以了解细胞和分子机制.
- 研究蛋白质修饰的研究,如心脏毒性的泛化和酸化.
主要成果:
- 化疗剂可以导致心肌细胞变形,收缩功能障碍和纤维化.
- 目前的治疗方法,如ACE抑制剂和β抑制剂,可以控制症状,但不能预防细胞死亡.
- 多omics方法建议针对特定的途径和蛋白质修饰作为潜在的治疗策略.
结论:
- 对于预防和管理癌症幸存者心血管缺陷的新疗法有着至关重要的需求.
- 针对特定的分子途径和蛋白质修饰,为未来的治疗提供了有前途的途径.
- 确定新的生物标志物和治疗目标对于改善癌症患者的长期结果至关重要.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:46Electron Transport Chain: Complex I and II
10.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.7K
01:26Heart Failure Drugs: Inotropic Agents
510
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K